These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1290 related articles for article (PubMed ID: 31237055)

  • 1. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
    Tang H; Zhao X; Jiang X
    Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
    Verma R; Sahu R; Singh DD; Egbo TE
    Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Delivery Systems for CRISPR.
    Xu CL; Ruan MZC; Mahajan VB; Tsang SH
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
    Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
    Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
    Li L; Hu S; Chen X
    Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
    Wan T; Ping Y
    Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
    Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
    Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
    Wang L; Zheng W; Liu S; Li B; Jiang X
    Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-mediated correction of human genetic disease.
    Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
    Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.